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Summary  The  global  burden  of  tuberculosis  (TB)  is  still  large.  The  increasing  inci-
dence  of  drug-resistant,  multidrug-resistant  (MDR)  (resistant  to  at  least  rifampicin
and  isoniazid),  and  extensively  drug-resistant  (XDR)  (additionally  resistant  to  a
ﬂuoroquinolone  and  kanamycin/amikacin/capreomycin)  strains  of  Mycobacterium
tuberculosis  and  the  association  of  active  disease  with  human  immunodeﬁciency
virus  coinfection  pose  a  major  threat  to  TB  control  efforts.  The  rapid  detection  of
M.  tuberculosis  strains  and  drug  susceptibility  testing  (DST)  for  anti-TB  drugs  ensure
the  provision  of  effective  treatment.  Rapid  molecular  diagnostic  and  DST  methods
have  been  developed  recently.  Treatment  of  drug-susceptible  TB  is  effective  in  ≥95%
of  disease  cases;  however,  supervised  therapy  for  ≥6  months  is  challenging.  Non-
adherence  to  treatment  often  results  in  the  evolution  of  drug-resistant  strains  of
M.  tuberculosis  due  to  mutations  in  the  genes  encoding  drug  targets.  Sequential
accumulation  of  mutations  results  in  the  evolution  of  MDR  and  XDR  strains  of  M.
tuberculosis.  Effective  treatment  of  MDR-TB  involves  therapy  with  5—7  less  effec-
tive,  expensive,  and  toxic  second-line  and  third-line  drugs  for  ≥24  months  and  is
difﬁcult  in  most  developing  countries.  XDR-TB  is  generally  an  untreatable  disease
in  developing  countries.  Some  currently  existing  drugs  and  several  new  drugs  with
novel  modes  of  action  are  in  various  stages  of  development  to  shorten  the  treatment
duration  of  drug-susceptible  TB  and  to  improve  the  outcome  of  MDR-TB  and  XDR-TB.
©  2013  King  Saud  Bin  Abdulaziz  University  for  Health  Sciences.  Published  by  Elsevier
Ltd.  All  rights  reserved.∗ Corresponding author at: Department of Microbiology, Faculty of 
ox 24923, Safat 13110, Kuwait. Tel.: +965 2498 6503; fax: +965 2531
E-mail addresses: suhail ah@hsc.edu.kw, suhail ah2000@yahoo.co
876-0341/$ — see front matter © 2013 King Saud Bin Abdulaziz University for Health
ttp://dx.doi.org/10.1016/j.jiph.2013.09.001Medicine, AMAR Health Sciences Center, Kuwait University, P.O.
 8454.
m (S. Ahmad).
 Sciences. Published by Elsevier Ltd. All rights reserved.
76  S.  Ahmad,  E. Mokaddas
Contents
Introduction..................................................................................................  76
Global  epidemiology  of  TB,  drug-resistant  TB,  MDR-TB,  and  XDR-TB..........................................  76
Diagnosis  of  active  TB  disease................................................................................  77
Chemotherapy  for  TB  and  the  evolution  of  drug-resistant  TB.................................................  77
Anti-TB  drugs:  mechanism  of  action  and  molecular  basis  of  resistance  .......................................  78
Diagnosis  of  drug-resistant  TB,  MDR-TB,  and  XDR-TB  .........................................................  81
Treatment  of  drug-resistant  TB,  MDR-TB,  and  XDR-TB  ........................................................  82
Drug-resistant  TB  in  children.................................................................................  85
Drug-resistant  TB  in  HIV-coinfected  patients  .................................................................  85
Clinical  re-evaluation  of  existing  anti-tubercular  drugs.......................................................  85
New  drugs  under  clinical  evaluation  and  preclinical  development  ............................................  86
Conclusion  ...................................................................................................  87
Acknowledgements...........................................................................................  88
References ...................................................................................................  88
Introduction
Despite  a  slow  decline  in  the  incidence  of  tuber-
culosis (TB)  in  recent  years,  the  global  burden  of
TB is  still  large.  Active  disease  is  mainly  caused
by Mycobacterium  tuberculosis. The  inhalation  of
droplet nuclei  containing  a  few  bacilli  during  close
human contact  with  sputum  smear-positive  pul-
monary  TB  patients  results  in  new  TB  infections.
However, primary  infection  with  M.  tuberculosis
only leads  to  clinically  active  TB  disease  in  ∼10%
of exposed  individuals.  In  other  immunocompetent
hosts, an  effective  immune  response  arrests  fur-
ther multiplication  of  tubercle  bacilli,  but  complete
pathogen clearance  is  achieved  by  only  a  few  indi-
viduals.  The  sub-optimal  immune  response  of  the
remaining  subjects  only  succeeds  in  containing  the
infection, as  some  bacilli  escape  killing  and  per-
sist in  a  dormant  state  in  granulomatous  lesions.
The latent  infection  may  remain  dormant  for  a long
time; however,  M.  tuberculosis  can  reactivate  and
cause active  TB,  typically  due  to  weakening  of  the
immune  system  [1].  The  World  Health  Organization
(WHO) has  estimated  that  one-third  of  the  total
world  population  is  latently  infected  with  tuber-
cle bacilli  and  that  5—10%  of  infected  individuals
will develop  active  TB  during  their  lifetime  [1,2].
Reactivation  of  latent  infection  occurs  more  fre-
quently  (5—15%  per  year  and  ∼50%  over  a  lifetime)
in human  immunodeﬁciency  virus  (HIV)-coinfected
individuals  [3].
The  reactivation  of  latent  infection  is  largely
responsible for  active  TB  in  countries  with  low  TB
incidence,  while  recent  infection  and  re-infection
ﬁrst-line  and  important  second-line  anti-TB  drugs
and the  growing  population  of  HIV-coinfected  and
other immunocompromised/immunosuppressed
individuals  with  underlying  conditions  such  as
diabetes  [2,3,5].
Global epidemiology of TB,
drug-resistant TB, MDR-TB, and XDR-TB
According  to  annual  WHO  surveys,  8.7  million  new
and relapse  cases  of  active  TB  (estimated  inci-
dence of  125  per  100,000  population)  occurred  in
2011 [2]. Nearly  1.1  million  (13%)  TB  patients  were
coinfected  with  HIV.  The  estimated  cases  mostly
occurred  in  Asia  (59%)  and  Africa  (26%).  Approx-
imately 7.7%,  4.3%,  and  3%  of  cases  occurred  in
the Eastern  Mediterranean  region,  the  European
region, and  the  Region  of  the  Americas,  respec-
tively. The  22  countries  with  a high  TB  burden
accounted for  82%  of  all  cases,  while  the  high-
est incidence  rate  (262  per  100,000  population)
was recorded  for  the  African  region,  mainly  due
to a  higher  prevalence  of  HIV  coinfection.  Glob-
ally, the  12  million  TB  cases  in  2011  resulted  in
1.4 million  deaths  (including  430,000  among  HIV-
coinfected  individuals)  [2].
The WHO  has  also  collected  drug  susceptibility
testing (DST)  data  for  the  isoniazid  (INH),  rifampicin
(RIF), ethambutol  (EMB),  and  streptomycin  (SM)
ﬁrst-line drugs.  Phenotypic  DST  for  another  ﬁrst-
line drug,  pyrazinamide  (PZA),  is  not  routinely
performed because  the  drug  is  active  at  acidicare also  common  in  countries  with  a  high  TB
burden [2,4].  Major  factors  sustaining  the  global
burden  of  TB  include  the  increasing  incidence  of  M.
tuberculosis  strain  resistance  to  the  most  effective
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wH values,  which  complicates  susceptibility  test-
ng [6]. Recent  data  showed  that  resistance  to  at
east one  anti-TB  drug  (deﬁned  as  any  resistance)
as 11.1%  among  new  TB  cases  and  was  higher
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mong  previously  treated  patients  [7]. Worldwide,
.7% of  new  cases  and  20%  of  previously  treated
ases (totaling  ∼630,000  cases)  are  now  deﬁned  as
ultidrug-resistant  TB  (MDR-TB,  infection  with  an
. tuberculosis  strain  that  is  resistant  to  at  least  RIF
nd INH,  the  two  most  effective  anti-TB  drugs)  [2].
he 27  countries  with  a  high  MDR-TB  burden  con-
ain >90%  of  cases,  while  India,  China,  the  Russian
ederation, and  South  Africa  account  for  ∼60%  of
ll MDR-TB  cases  [2]. XDR-TB  (deﬁned  as  infection
ith MDR-TB  strains  that  are  additionally  resis-
ant to  a  ﬂuoroquinolone  and  an  injectable  agent
uch as  kanamycin,  amikacin,  or  capreomycin)  was
etected  in  84  countries.  Approximately  9%  of  all
DR-TB  cases  are  projected  to  be  XDR-TB,  and  an
stimated  25,000  cases  of  XDR-TB  are  emerging
lobally every  year  [2,8]. Major  factors  in  the  man-
gement  of  TB  include  rapid  diagnosis  and  DST  of  M.
uberculosis  strains  to  ensure  effective  treatment
f all  patients,  particularly  those  with  infectious
ulmonary TB.
iagnosis of active TB disease
aboratory  diagnosis  of  active  TB  is based  on  smear
icroscopy  assessment  of  acid-fast  bacilli  (AFB),
rowth  of  M.  tuberculosis  in  solid  or  liquid  cul-
ure, and  detection  of  M.  tuberculosis  nucleic
cid in  clinical  specimens.  These  methods  vary
n cost,  turnaround  time,  and  laboratory  infra-
tructure requirements  [9].  Smear  microscopy  using
iehl—Neelsen  staining  is a  rapid  test  but  is  not
ensitive  (34—80%  of  positive  cultures)  and  is  often
egative  in  HIV-coinfected  pulmonary  TB  patients
ue to  paucibacillary  load.  Additionally,  DST  is  not
easible [10].
Deﬁnitive  diagnosis  of  active  TB  is  based  on  the
ulture  of  M.  tuberculosis  (regarded  as  the  gold
tandard),  especially  in  smear-negative  specimens,
nd enables  species-speciﬁc  identiﬁcation  and
ST to  guide  therapy  [6,10]. Culture  on  solid
Lowenstein-Jensen)  medium  is  time-consuming,
equiring 4—6  weeks  for  detectable  growth  and
n additional  2—3  weeks  for  species-speciﬁc  iden-
iﬁcation.  Liquid  (e.g.,  Middlebrook  7H9)  media
upports  more  rapid  growth.  Fully  automated  liquid
ulture systems  (such  as  the  BACTEC  mycobacteria
rowth indicator  tube  or  the  MGIT  960  culture  sys-
em) allow  for  the  recovery  of  mycobacteria  from
linical  specimens  within  14  days;  however,  addi-
ional time  is  needed  for  the  identiﬁcation  of  M.
uberculosis  [10]. The  Accuprobe  assay  can  identify
. tuberculosis  and  ﬁve  common  non-tuberculous
ycobacteria  (NTM)  in  ∼2  h  in  culture-positive
ubes.  Two  reverse  hybridization-based  line
c
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robe  assays  also  identify  M.  tuberculosis  and
everal  NTM  species  in  both  culture  isolates
nd clinical  specimens.  Simple,  rapid  (requiring
1 h),  and  relatively  inexpensive  oligochromato-
raphic/immunochromatographic  assays  have  also
een developed  for  the  detection  of  M.  tubercu-
osis and  NTM  species  in  culture-positive  samples
9,10].
Molecular  methods,  typically  involving  PCR/real-
ime PCR,  have  also  been  developed.  These  assays
re mainly  recommended  for  the  identiﬁcation  of
. tuberculosis  in  sputum  smear-positive  spec-
mens.  Commercial  tests  perform  better  than
n-house  developed  tests,  and  some  have  been
pproved  by  the  Food  and  Drug  Administration
FDA) of  the  USA  and  the  WHO  for  routine  diag-
osis of  TB.  These  tests  include  the  Cobas  TaqMan
TB test,  Ampliﬁed  Mycobacterium  Tuberculosis
irect (AMTD)  test,  BDProbeTec  ET  Mycobacterium
uberculosis  complex  direct  detection  assay,  and
eneXpert  MTB/RIF  (Xpert  MTB/RIF)  assay.  The
ooled sensitivity  of  these  tests  for  smear-positive
nd smear-negative  respiratory  samples  is  ∼95%
nd ∼70%,  respectively,  while  their  performance
n extrapulmonary  specimens  is  usually  much  lower
9,10].
The Xpert  MTB/RIF  assay  is  a point-of-care  TB
iagnostic test  [11].  Although  originally  intended
or respiratory  specimens,  it has  also  performed
ell for  a variety  of  non-respiratory  samples.  Xpert
TB/RIF  has  detected  98—100%  of  smear-positive
nd 57—83%  of  smear-negative  pulmonary  TB  sam-
les. A  sensitivity  of  53—95%  has  been  reported
or extrapulmonary  specimens  [12]. The  WHO  has
trongly recommended  the  Xpert  MTB/RIF  assay
herever  possible,  particularly  for  HIV-coinfected
ndividuals [2].
hemotherapy for TB and the evolution
f  drug-resistant TB
rolonged  multidrug  therapy  for  TB  is  required
ecause M.  tuberculosis  grows  very  slowly  and
as an  increased  capacity  for  dormancy  (low
etabolic activity).  Successful  treatment  (conver-
ion of  sputum  from  culture-positive  to  culture-
egative within  2 months)  depends  on  the  duration
nd combination  of  drugs  being  prescribed,  the
atient’s  adherence  to  treatment,  and  adverse  drug
eactions. The  preferred  treatment  regimen  for
ulmonary  TB  caused  by  drug-susceptible  M.  tuber-
ulosis in  both  HIV-coinfected  and  HIV-seronegative
dults, which  is  endorsed  by  the  American  Thoracic
ociety  (ATS),  includes  daily  therapy  or  therapy
 days/week  (when  drugs  are  administered  under
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directly  observed  therapy  [DOT])  with  INH,  RIF,
PZA, and  EMB  for  2 months  in  the  initial  phase
of treatment.  The  4-month  continuation  phase
of treatment  includes  daily  therapy  or  therapy  5
days/week  (when  drugs  are  given  under  DOT)  with
INH and  RIF  [13].  However,  patients  with  cavita-
tion on  their  initial  chest  radiograph  and/or  with
positive  cultures  after  2  months  of  therapy  receive
a 7-month  continuation  phase  of  treatment  with
either daily  or  twice  weekly  therapy  with  INH  and
RIF. The  6-month  treatment  course  is  also  recom-
mended for  extrapulmonary  TB  involving  any  site
except the  meninges,  in  which  case  a  9-  to  12-
month regimen  is  recommended  [13].
Treatment  of  HIV—TB  coinfected  patients  is  com-
plicated  by  drug—drug  interactions  and  may  require
the substitution  of  RIF  with  other  rifamycins  [13].
Other common  co-morbidities,  such  as  diabetes,
may also  complicate  treatment  [14].  Treatment
of drug-susceptible  TB  is  possible  in  ≥95%  of  dis-
ease cases;  however,  supervised  therapy  for  ≥6
months  is challenging.  TB  patient  intolerance  to
one or  more  drugs  and  non-adherence  to  treat-
ment often  result  in  much  lower  cure  rates  and
the evolution  of  drug-resistant  strains  of  M.  tuber-
culosis  [13,15]. Resistance  of  M.  tuberculosis  to
anti-TB drugs  is  caused  by  chromosomal  mutations
occurring at  a  frequency  of  10−3—10−9 in  genes
encoding  drug  targets.  Because  the  probability  of
two independent  mutations  conferring  resistance  to
two anti-TB  drugs  in  a  single  bacillus  is  much  lower
(10−12—10−15),  most  TB  patients  do  not  contain
any such  strains  if  they  have  never  been  previously
exposed to  anti-TB  drugs  [13,15].  However,  during
inappropriate  therapy,  only  drug-susceptible  strains
are killed,  while  drug-resistant  strains  survive  and
multiply. Sequential  accumulation  of  mutations
results in  the  evolution  of  MDR-TB  strains  [8,13,15].
Effective treatment  of  MDR-TB  is  more  difﬁcult  than
that of  drug-susceptible  TB  and  often  results  in
relapse  or  treatment  failure,  particularly  among
HIV-coinfected  patients  [16—18].  Incomplete  or
improper  treatment  of  MDR-TB  patients  further
ampliﬁes drug  resistance  in  M.  tuberculosis  strains
and leads  to  the  emergence  of  XDR-TB  [2,8].
The emergence  of  MDR-TB  has  resulted  in  the
development of  novel  methods  for  rapid  diagnosis
and effective  treatment  strategies  with  several
old and  new  anti-TB  agents.  Anti-TB  drugs  are  now
recognized  as  ﬁrst-line  (most  effective),  second-
line (less  effective,  more  toxic),  and  third-line
(reinforcing)  agents  based  on  their  efﬁcacy  and  tol-
erability (Table  1).  First-line  (Group  1)  drugs  (INH,
RIF, EMB,  and  PZA)  are  highly  effective,  relatively
less toxic  than  other  anti-TB  drugs,  and  mostly
bactericidal oral  agents  suitable  for  combination
p
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herapy.  Because  SM  must  be  administered  intra-
uscularly,  it is now  used  as  a  second-line  agent
ue to  the  requirement  for  frequent  patient  visits
o health  care  facilities,  higher  rates  of  resis-
ance among  clinical  M.  tuberculosis  isolates,  and
he availability  of  more  effective  anti-TB  drugs.
ther rifamycins  (rifabutin,  RBU;  and  rifapen-
ine, RPE),  although  more  expensive,  may  be
sed in  place  of  RIF  in  select  patient  populations
13,15].
Second-line  agents  have  been  further  divided
nto three  different  groups  (Groups  2—4)  based  on
heir mode  of  action,  route  of  entry,  and  potency.
roup 2  includes  injectable  aminoglycosides  (SM,
treptomycin;  kanamycin,  KAN;  and  amikacin,  AMI)
nd cyclic  polypeptides  (capreomycin,  CAP;  and
iomycin,  VIO)  [13,15]. Flouroquinolones  (FQs)
Group 3  oral/injectable  agents)  include  oﬂoxacin
OFX),  levoﬂoxacin  (LFX),  moxiﬂoxacin  (MFX),  and
atiﬂoxacin (GFX).  Higher  doses  of  older  FQs,
amely,  OFX  and  LFX,  have  been  safely  adminis-
ered. GFX  and  MFX  at regular  doses  and  LFX  at
igher doses  are  bactericidal  [19].  Group  4  includes
ainly  bacteriostatic,  less  efﬁcacious,  expensive,
nd more  toxic  oral  agents,  such  as  ethionamide
ETA), prothionamide  (PTA),  D-cycloserine  (CS),  ter-
zidone (TZD),  and  para-amino  salicylic  acid  (PAS),
hat are  used  mainly  for  the  treatment  of  MDR-
B and  XDR-TB  based  on  the  susceptibility  of  M.
uberculosis  strains  (Table  1)  [13,15—18].
Third-line (Group  5)  reinforcing  agents,  such  as
inezolid (LZD)  at  the  full  or  half  dose  (to  reduce
oxicity), amoxicillin—clavulanate  (AMX—CLV),
eropenem—clavulanate  (MEP—CLV),  clofazimine
CFZ), and  thiacetazone  (TAC),  have  been  used
ccasionally  for  the  treatment  of  MDR-TB  and
DR-TB but  are  not  recommended  for  routine  use
ue to  variable  efﬁcacy  and  serious  side  effects.
hiacetazone is  highly  toxic  and  is  contraindicated
or HIV-coinfected  TB  patients  [20—22].
nti-TB drugs: mechanism of action and
olecular basis of resistance
he  genes  and  their  target  regions  that  are  involved
n mediating  the  resistance  of  M.  tuberculosis  to
rst-line  and  important  second-line  anti-TB  drugs
re summarized  in  Table  2.
Isoniazid (INH),  a pro-drug,  has  potent  activ-
ty against  actively  dividing  M.  tuberculosis.
NH is  activated  by  the  katG-encoded  catalase-
eroxidase. Activated  INH  mainly  targets  NADH-
peciﬁc  enoyl-acyl  carrier  protein  (ACP)  reductase
inhA),  which  is  involved  in  mycolic  acid  synthesis.
epletion of  mycolic  acids  results  in  bacterial  killing
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Table  1  First-line,  second-line  and  some  third-line  drugs  currently  in  use  for  the  treatment  of  drug-susceptible
and  drug-resistant  tuberculosis.
Category  and  drug  Chemical  description  Daily  adult
dosea (mg)
Efﬁcacy
Group  1:  ﬁrst-line  oral  drugs
Isoniazid,  INH  Nicotinic  acid  hydrazide  300  Bactericidal
Rifampin,  RMP  Rifamycin  derivative  600  Bactericidal
Pyrazinamide,  PZA Nicotinamide  derivative 2000  Bactericidal
Ethambutol,  EMB Ethylene  diimino  di-1-butanol 1200  Bacteriostatic
Group  2:  second-line,  injectable  agents
Streptomycin,  SM Aminoglycoside  1000  Bactericidal
Kanamycin,  KAN  Aminoglycoside  1000  Bactericidal
Amikacin,  AMI  Aminoglycoside  1000  Bactericidal
Capreomycin,  CAP  Cyclic  polypeptide  1000  Bactericidal
Viomycin,  VIO Cyclic  polypeptide 1000  Bactericidal
Group  3:  second-line,  ﬂuoroquinolones
Oﬂoxacin,  OFX  Fluoroquinolone  800  Bacteriostatic
Levoﬂoxacin,  LFX  Fluoroquinolone  750  Bactericidalb
Gatiﬂoxacin,  GFX  8-Methoxy-ﬂuoroquinolone  400  Bactericidal
Moxiﬂoxacin,  MFX  8-Methoxy-ﬂuoroquinolone  400  Bactericidal
Group  4:  second-line,  oral  agents
Ethionamide,  ETA  Isonicotinic  acid  derivative  750  Bacteriostatic
Prothionamide,  PTA  Isonicotinic  acid  derivative  750  Bacteriostatic
D-Cycloserine,  CS  Serine  derivative  750  Bacteriostatic
Terizidone,  TRD  Serine  derivative  750  Bacteriostatic
Para-amino  salicylic  acid,  PAS  Para-amino  salicylic  acid  8000  Bacteriostatic
Group  5:  third-line,  oral  agents
Linezolid,  LZD  Oxazolidinone  derivative  1200  Bactericidal
Amoxycillin—clavulanate,  AMX—CLV  -Lactam  with  -lactamase  inhibitor  2000—250  Bactericidal
Imipenem—clavulanate,  IMP—CLV Carbapenem  with  -lactamase  inhibitor  2000—250  Bactericidal
Meropenem—clavulanate,  MEP—CLV  Carbapenem  with  -lactamase  inhibitor  3000—250  Bactericidal
Clofazimine,  CFZ Iminophenazine  derivative  200  Bacteriostatic
Thiacetazone,  TAC Thiosemicarbazone  derivative 150  Bacteriostatic
a Total daily adult dose for a tuberculosis patient weighing >51 kg.
b At high dose (1000 mg).
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o23,24].  The  molecular  basis  of  resistance  to  INH
s complex,  as  resistance-conferring  mutations  are
ound in  several  genes.  High-level  resistance  to  INH
s mainly  due  to  mutations  within  the  katG  gene,
hile mutations  in  the  inhA  regulatory  region  con-
er low-level  resistance  to  INH  in  M.  tuberculosis
solates [23,24]. KatG  mutations  occur  frequently
∼50—95%), particularly  at  codon  315  (katG315),
n  INH-resistant  M.  tuberculosis  strains  [23—25].
he frequency  of  mutations  in  the  inhA  regulatory
egion also  varies  in  INH-resistant  strains  [24,26].
utations in  other  genes  and  the  induction  of  efﬂux
umps  are  also  involved,  but  have  a  minor  role,  in
NH resistance  [24].
Rifampicin  (RIF)  binds  to  the  rpoB-encoded
-subunit  of  RNA  polymerase  and  inhibits  RNA  tran-
cription/protein  synthesis.  Monoresistance  to  RIF
i
p
t
bs  rare  except  in  patients  with  HIV-coinfection
r other  underlying  diseases.  Because  nearly
5—90% of  RIF-resistant  M.  tuberculosis  isolates
re also  resistant  to  INH,  resistance  to  RIF  is
egarded as  a  surrogate  marker  for  MDR-TB  [24,27].
pproximately  90—95%  of  RIF-resistant  M.  tuber-
ulosis  isolates  contain  mutations  within  an  81-bp
ifampicin  resistance-determining  region  (RRDR)
spanning  rpoB  codons  507—533,  Escherichia  coli
umbering  system).  Resistance  in  5—10%  of  iso-
ates is  due  to  mutations  in  the  N-terminal  (codon
146) or  cluster  II  regions  of  the  rpoB  gene  or
ther genes  [24,26]. Compensatory  mutations  that
mprove competitive  ﬁtness  occur  in  other  RNA
olymerase  (rpoA,  rpoC)  genes  in  RIF-resistant  M.
uberculosis  strains  [28].  While  cross-resistance
etween RIF  and  RPE  is  common,  ∼12—20%  of
80  S.  Ahmad,  E. Mokaddas
Table  2  Main  gene  targets  conferring  resistance  to  ﬁrst-line  and  some  important  second-line  antitubercular  agents
in  Mycobacterium  tuberculosis.
Anti-TB  druga Gene
target
Encoded  product  Main  target  region  Relative  frequency  in
resistant  strains  (%)
RIF  rpoB  -Subunit  of  RNA  polymerase  81  bp  RRDRb 90—95
RIF  rpoB  -Subunit  of  RNA  polymerase  N-terminal  region  2—5
INH  katG  Catalase/peroxidase  Entire  gene  50—95
INH  inhA  Enoyl-ACP  reductase  Regulatory  region  5—43
PZA  pncA  Pyrazinamidase  Many  codons  68—95
EMB  embB  Arabinosyl  transferase Many  codons 35—89
SM  rpsL  Ribosomal  S12  Protein Few  codons 20—81
SM  rrs  16S  rRNA  Few  nucleotides  10—30
FQs  gyrA  DNA  gyrase,  A  subunit  Few  codons  58—90
FQs  gyrB  DNA  gyrase,  B  subunit  Few  codons  2—8
KAN/AMI  rrs  16S  rRNA  3′-end  of  16S  rRNA  80—85
KAN  eis  Aminoglycoside  acetyltransferase  Regulatory  region  20—25
CAP  rrs  16S  rRNA  3′-end  of  16S  rRNA  80—85
CAP  tlyA  Cytotoxin/haemolysin  homologue  Several  codons  6—10
a RIF, rifampicin; INH, isoniazid; PZA, pyrazinamide; EMB, ethambutol; FQs, ﬂuoroquinolones (oﬂoxacin, levoﬂoxacin, gati-
ﬂoxacin and moxiﬂoxacin); KAN, kanamycin; AMI, amikacin; CAP, capreomycin.
b RRDR, rifampicin resistance determining region.
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[RIF-resistant  strains  remain  susceptible  to  RBU,
making  RBU  a  useful  drug  for  the  treatment  of  some
patients  [29].
Pyrazinamide  (PZA),  a  pro-drug,  is  highly  effec-
tive against  semi-dormant  bacilli  in  an  acidic
environment (such  as  the  phagosome)  [13,15]. PZA
is activated  by  pyrazinamidase  (PncA)  to  form
pyrazinoic acid,  which  inactivates  a  vital  step
in fatty  acid  synthesis.  PZA  also  inhibits  protein
translation and  the  ribosome-sparing  process  of
translation  by  binding  to  ribosomal  protein  S1
(RpsA) in  M.  tuberculosis.  Most  (68—95%)  PZA-
resistant M.  tuberculosis  strains  contain  mutations
in pncA  or  rpsA  [24,30,31].
Ethambutol  (EMB)  inhibits  the  synthesis  and  poly-
merization  of  cell  wall  arabinan,  which  leads  to
the accumulation  of  free  mycolic  acids  and  incom-
plete  cell  wall  assembly.  EMB  mainly  interacts
with membrane-associated  arabinosyltransferases
encoded  by  three  contiguous  genes  (embCAB
operon) as  an  arabinose  analog  [32].  The  molec-
ular basis  of  resistance  to  EMB  is  not  completely
deﬁned. Resistance-conferring  mutations  in  three
emb genes  have  been  identiﬁed  in  M.  tubercu-
losis strains,  and  mutations  in  embB  occur  most
frequently (20—89%),  particularly  at  embB  codon
306 (embB306), embB406, and  embB497  [24,32,33].
Some EMB-resistant  M.  tuberculosis  strains  do  not
contain a  mutation  in  any  of  the  genes  currently
implicated in  EMB  resistance  [24].
Streptomycin  (SM)  is  now  used  as  a  second-
line drug  for  treating  patients  who  have  failed
l
ﬂ
hherapy  or  have  MDR-TB  only  if  the  M.  tubercu-
osis strain  is  susceptible  to  SM  [13]. SM  inhibits
rotein synthesis  by  binding  to  a  ribosomal  pro-
ein (RpsL)  and  16S  rRNA.  High-level  resistance
ainly involves  missense  mutations  in  rpsL  codon
3 (rpsL43)  and  rpsL88,  while  mutations  in  the
rs gene  cause  low-level  resistance  [24,34]. Other
argets causing  low-level  resistance  to  SM  in  M.
uberculosis  include  the  gidB  gene,  which  encodes
-methylguanosine  (m7G)  methyltransferase  and
fﬂux pumps  [24,35].
Other aminoglycosides,  such  as  KAN  and  AMI,
nd cyclic  polypeptides,  such  as  CAP  and  VIO,  also
nhibit protein  synthesis  in  M.  tuberculosis  and
re used  as  bactericidal  second-line  drugs  [13,24].
esistance to  KAN  and  AMI  is  mainly  associated  with
utations  in  the  rrs  gene,  while  mutations  in  the
rs gene  and  rRNA  methyltransferase  (TlyA)  con-
er resistance  to  CAP  and/or  VIO  in  M.  tuberculosis
24,36].  Cross-resistance  between  KAN  and  AMI  or
etween KAN  and  CAP  or VIO  occurs  in  variable  pat-
erns, and  strains  that  are  resistant  to  KAN,  AMI,
nd CAP  but  susceptible  to  VIO  have  been  described
36,37].  Interestingly,  some  strains  that  are  resis-
ant to  KAN,  AMI,  and  CAP  but  are  susceptible  to
M have  also  been  described.  Thus,  SM  may  also  be
seful for  the  treatment  of  some  XDR-TB  patients
38].Fluoroquinolones  (FQs)  include  oﬂoxacin  (OFX),
evoﬂoxacin  (LFX),  moxiﬂoxacin  (MFX),  and  gati-
oxacin (GFX).  OFX  is  bacteriostatic,  while  LFX  (at
igh doses),  GFX,  and  MFX  are  bactericidal  and
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Miagnosis  and  treatment  of  tuberculosis  
uitable  agents  for  combination  therapy  [15,19].
Qs inhibit  DNA  gyrase  (a  type  II  topoisomerase),
hich consists  of  two  A  and  two  B  subunits  (encoded
y the  gyrA  and  gyrB  genes,  respectively),  and
ause cell  death  due  to  inhibition  of  DNA  replication
nd repair.  Mutations  in  small  regions  of  the  gyrA
mostly  codon  90  or  94)  and  gyrB  genes  or  changes
n drug  efﬂux  pumps  confer  resistance  to  FQs
n M.  tuberculosis  isolates  [39].  Cross-resistance
etween  different  FQs  is  not  100%,  as  some  OFX-
esistant strains  are  susceptible  to  MFX  and  vice
ersa [40].
iagnosis of drug-resistant TB, MDR-TB,
nd  XDR-TB
onventional  DST  methods  detect  M.  tuberculosis
rowth in  the  presence  of  antibiotics  by  one  of
hree  methods  (absolute  concentration,  resistance
atio,  or  proportion  method)  on  solid  (Lowenstein-
ensen) medium,  but  they  require  2—4  weeks  to
btain results  from  primary  culture.  The  broth-
ased fully  automated  culture  systems  (such  as  the
actec MGIT  960  TB  system)  are  now  routinely  used
or ﬁrst-  and  second-line  anti-TB  DST  of  M.  tuber-
ulosis  and  report  results  within  5—8  days  from  a
rimary  culture  [6]. Direct  DST  with  smear-positive
pecimens has  also  been  recently  reported  for  INH
nd RIF  with  the  Bactec  MGIT  960  system,  which
eliably detects  MDR-TB  cases  within  8—10  days
41].
Simple,  inexpensive  non-commercial  phenotypic
ethods have  also  been  developed  for  DST  of  M.
uberculosis  in  resource-poor  settings  [42].  These
ethods  include  the  microscopic  observation  drug
usceptibility  (MODS)  test,  thin  layer  agar  (TLA)
ethod,  nitrate  reductase  (NR)  assay,  colorimet-
ic redox  indicator  (CRI)  methods,  and  phage-based
ssays. Of  these  methods,  the  MODS,  NR,  and  CRI
ssays  have  been  endorsed  by  the  WHO  [2,6,8,42].
The MODS  test  is  performed  in  24-well  plates.
putum is  directly  inoculated  into  Middlebrook  7H9
roth containing  ﬁrst-line  anti-TB  drugs,  and  the
ording growth  of  M.  tuberculosis  is  detected  by
n inverted  microscope.  A  large  number  of  sam-
les can  be  tested,  and  results  are  available  within
—9 days  and  exhibit  ≥95%  agreement  with  conven-
ional  DST  for  INH,  RIF,  and  MDR-TB.  The  thin  layer
gar (TLA)  method  is  a  modiﬁcation  of  the  MODS
ssay for  the  detection  of  MDR-TB  and  XDR-TB  in
ultures [42].
The  NR  assay  detects  pink-red  color  due  to  the
eduction of  nitrate  to  nitrite  by  viable  M.  tuber-
ulosis, usually  within  7—10  days.  A  large  number
f samples  can  be  processed,  and  the  sensitivity  for
P
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etection  of  MDR-TB  and  XDR-TB  is  ≥95%.  Because
he NR  assay  only  detects  bacterial  growth,  it  may
ield false-positive  results  and  is also  unable  to
etect rare  nitrate  reductase-negative  M.  tuber-
ulosis  [42]. The  CRI  methods  are  based  on  the
eduction of  indicators  such  as  tetrazolium  salts  and
esazurin, which  are  added  to  culture  medium  in
he presence  of  anti-TB  drugs.  Results  are  usually
vailable  within  8—10  days.  These  methods  have
een evaluated  for  the  detection  of  MDR-TB  and
DR-TB  strains  [42].
Phage-based  assays  use  mycobacteriophages  to
etect the  presence  or  growth  of  M.  tuberculosis  by
sing a phage  ampliﬁcation  assay  or  the  more  sensi-
ive luciferase  reporter  mycobacteriophages  in  the
bsence or  presence  of  anti-TB  drug(s).  Viable  M.
uberculosis  growing  in  the  presence  of  anti-TB
rugs emits  light  in  the  presence  of  luciferin  and
s identiﬁed  as  a drug-resistant  strain  [52].
Molecular methods  detect  resistance-associated
utations  in  the  target  genes  of  M.  tuberculosis  and
ield results  within  1—2  days.  Both  clinical  isolates
f M.  tuberculosis  and  smear-positive  (and  some-
imes smear-negative)  clinical  samples  are  used
or rapid  identiﬁcation  of  MDR-TB  and  XDR-TB  [9].
etection of  RIF  resistance  is  simple,  as  90—95%
f RIF-resistant  strains  contain  mutations  in  the
1-bp RRDR  of  the  rpoB  gene.  RIF  resistance  detec-
ion also  identiﬁes  most  MDR-TB  strains,  as  85—90%
f RIF-resistant  M.  tuberculosis  isolates  are  also
esistant  to  INH  [24].  Some  molecular  tests  for  TB
iagnosis  (Xpert  MTB/RIF)  simultaneously  detect
esistance  to  RIF  and,  thus,  the  majority  of  MDR-TB
trains  [11,12]. The  sensitivity  of  resistance  detec-
ion for  other  drugs  varies  considerably.  Although
olecular assays  targeting  multiple  gene  loci  have
een recently  developed,  they  still  do  not  detect  all
esistant strains  [9]. Real-time  PCR  (RT-PCR)  assays
etect dominant  mutations  conferring  resistance  to
NH, RIF,  SM,  KAN/AMI/CAP,  and  FQs  by  using  ﬂuoro-
enic probes  or  performing  high-resolution  melting
urve  analysis  of  RT-PCR  amplicons  for  the  identi-
cation  of  MDR-TB  and  XDR-TB  strains  in  clinical
pecimens and/or  culture  isolates  [9,43].
PCR ampliﬁcation  of  target  regions,  followed  by
equencing  or  pyrosequencing  of  amplicons,  has
lso been  used  for  the  detection  of  MDR-TB  and
DR-TB  strains  in  culture  isolates  and  clinical  spec-
mens. Direct  DNA  sequencing  analysis  in  sputum
including smear-negative,  culture-positive)  sam-
les detected  64%,  96%,  69%,  100%,  and  50%  of
. tuberculosis  strains  resistant  to  INH,  RIF,  EMB,
ZA, and  INH  +  RIF  (MDR-TB),  respectively  [44].
lthough complete  genome  sequencing  is  not  yet
ractical with  clinical  specimens,  it may  become
outine in  the  near  future,  enabling  the  detection  of
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resistance-conferring  mutations  in  multiple  target
genes of  MDR-TB  and  XDR-TB  strains  [45].
Three commercial  reverse  hybridization-based
line  probe  assays  have  also  been  developed.
INNO-LiPA  Rif.  TB  detects  M.  tuberculosis  and  its
resistance  to  RIF,  but  it  can  also  predict  the  MDR  sta-
tus of  ∼85—90%  of  M.  tuberculosis  strains.  Pooled
sensitivities of  ∼93%  and  ∼65%  are  reported  for  the
detection of  M.  tuberculosis  from  smear-positive
and smear-negative  sputum  samples,  respectively.
Pooled sensitivities  for  RIF  resistance  detection
ranged from  88  to  97%  and  77  to  99%  for
smear-positive  and  smear-negative  sputum  sam-
ples, respectively  [9]. The  Genotype  MTBDRplus
assay  detects  RIF  and  INH  resistance  (MDR-TB
strains) in  culture  isolates  and  sputum  samples
[9,26].  The  sensitivity  for  the  detection  of  M.
tuberculosis  in  smear-positive  samples  is  78—98%,
but it  is  lower  for  smear-negative  pulmonary  and
extrapulmonary  specimens  [9,46].  Pooled  sensitiv-
ity for  RIF  resistance  is  ∼98%  in  culture  isolates
and smear-positive  sputum  samples,  but  it  is  ∼89%
for INH  resistance  in  culture-conﬁrmed  cases  and
even lower  in  clinical  specimens.  The  sensitiv-
ity for  RIF  +  INH  resistance  (MDR-TB)  detection  in
culture isolates  and  smear-positive  sputum  sam-
ples has  been  reported  as  ∼85—90%  [9,26,46]. The
genotype  MTBDRsl  assay  detects  resistance  to  FQs,
injectable  drugs  (KAN/AMI/CAP),  and  EMB  in  cul-
ture isolates  and  clinical  specimens  [9]. Pooled
sensitivities of  genotype  MTBDRsl  for  the  detec-
tion of  resistance  to  FQs,  KAN,  AMI,  and  CAP  were
reported as  85%,  83%,  90%,  and  87%,  respectively
[9,47].  Genotype  MTBDRsl  and  genotype  MTBDRplus
together  detect  XDR-TB  strains,  reducing  the  time
to diagnosis  of  XDR-TB  in  high-prevalence  settings
[48].
Treatment of drug-resistant TB, MDR-TB,
and  XDR-TB
Monodrug-resistant  TB  is caused  by  an  M.  tubercu-
losis  strain  that  grows,  in  vitro,  in  the  presence  of
one anti-TB  drug.  Polydrug-resistant  TB  is deﬁned
as resistance  to  various  combinations  of  ﬁrst-line
drugs, excluding  INH  + RIF.  The  resistance  proﬁle
of an  M.  tuberculosis  strain  is  the  most  impor-
tant strain  characteristic,  as  treatment  regimens
and durations  are  devised  according  to  the  pro-
ﬁle [13,49].  The  minimum  number  of  active  drugs
and  the  duration  of  treatment  for  infections  caused
by M.  tuberculosis  strains  with  different  resistance
patterns are  shown  in  Table  3.
[
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Monodrug  resistance  of  M.  tuberculosis  to  SM  is
ommon,  but  it is  rare  for  EMB.  Treatment  dura-
ion/failure for  SM-  or  EMB-resistant  TB  is  the  same
s that  for  susceptible  TB,  as  SM  is  no  longer  used
s a ﬁrst-line  drug,  while  EMB  is  used  only  during
he initiation  phase  and  is  easily  replaced  by  oral
Qs [13,15].  Treatment  of  INH-resistant  TB  with
 daily  9-month  regimen  of  RIF,  PZA,  and  EMB  in
ow-TB-incidence  countries  is  favorable.  For  other
ettings,  daily  therapy  for  >6  months  with  regi-
ens containing  RIF,  other  effective  drugs,  and
AN/AMI/CAP  yields  a better  prognosis  [13,50].
owever, under-detection  of  RIF  resistance  must  be
xcluded, which  may  be  difﬁcult  in  the  case  of  low-
evel RIF-resistant  strains  [9].  Monodrug-resistant
trains of  M.  tuberculosis  to  PZA  have  also  been
escribed  and  are  associated  with  a poorer  clin-
cal outcome  despite  a 9-month  treatment  with
IF-containing  regimens  [51].  Monoresistance  to
IF, the  most  effective  drug  against  non-replicating
ormant bacilli  (persisters),  occurs  rarely  (except
n HIV-coinfected  patients)  and  is  associated  with
oorer outcomes  and  higher  relapse  rates,  even
ith the  use  of  4  drug  regimens  for  >9  months,  but
utcomes  improve  with  12-month  therapy  [52].
Treatment  of  infections  involving  polydrug-
esistant (INH  + EMB,  INH  +  PZA,  EMB  +  PZA,  or
NH +  EMB  +  PZA)  M.  tuberculosis  strains  requires
areful clinical  evaluation  but  can  be  managed  with
xtended treatment  (∼18  months)  using  regimens
ontaining ﬁrst-line  drug(s),  FQs,  KAN/AMI/CAP,
nd some  second-line  agents.  However,  treatment
ailure  occurred  in  21%  of new  cases  of  preexis-
ing polydrug  resistance,  compared  with  8%  of  new
ases of  monodrug-resistant  TB,  particularly  when
IF was  used  for  <5  months  [52].
Treatment  of  MDR-TB  is  lengthy,  expensive,
oxic, and  associated  with  higher  rates  of  clinical
ailure  and  disease  relapse.  Successful  manage-
ent of  MDR-TB  requires  DST  for  ﬁrst-  and
econd-line drugs  and  monitoring  of  patients
or bacteriological  (sputum  smear  and  culture)
nd radiological  improvement  and  adverse  drug
eactions.  In  developing  countries,  treatment  of
DR-TB is  difﬁcult  due  to  delayed  diagnosis,  inad-
quate DST  facilities,  and  the  lack  of  adequate
upplies of  second-line  drugs.  Two  basic  treat-
ent approaches  are  used.  Either  standardized
reatment regimens  are  designed  based  on  rep-
esentative  drug-resistance  surveillance  data,  or
ndividualized  regimens  are  tailored  based  on  a  pre-
ious history  of  anti-TB  treatment  and  DST  results
16,53].
The clinical  approach  to  the  diagnosis  and  man-
gement  of  patients  suspected  to  have  multidrug-
esistant tuberculosis  is  presented  in  Fig.  1.
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Table  3  Desirable  number  of  effective  drugs  and  minimum  duration  of  treatment  for  patients  with  different
patterns  of  drug-resistant  TB,  MDR-TB  and  XDR-TB.
Resistance  of  M.  tuberculosis
strain  to  anti-TB  drug(s)a
Disease  status  Desirable  number  of  drugs
for  effective  treatment
Minimum  treatment
duration  (months)
None  Susceptible  TB  4  6
EMB  or  SM  Monodrug-resistant  TB  4  6
PZA  or  INH Monodrug-resistant  TB  4  6—9
RIF  Monodrug-resistant  TB 4—5 9—12
INH,  SM  or  EMB  or  PZA Polydrug-resistant  TB 4—5 6—9
INH,  EMB,  PZA Polydrug-resistant  TB 4—5 6—9
INH,  RIF  ±  EMB  MDR-TB  5—6 18—24
INH,  RIF,  PZA  ±  EMB  MDR-TB  5—7 24
INH,  RIF,  group  2  or  group  3  MDR-TB  5—7 >24
INH,  RIF,  group  2  +  goup  3  XDR-TB  5—7 >24
a EMB, ethambutol; SM, streptomycin; PZA, pyrazinamide; INH, isoniazid; RIF, rifampicin; Group 2, includes injectable agents
such as kanamycin, amikacin, capreomycin or viomycin; Group 3, includes ﬂuoroquinolones like oﬂoxacin, levoﬂoxacin, gatiﬂoxacin
or moxiﬂoxacin; Group 4, includes oral second-line drugs such as ethionamide, prothionamide, D-cycloserine, terizidone or para-
amino salicylic acid; Group 5, includes third-line reinforcing agents such as linezolid, amoxicillin—clavulanate, imipenem or
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dmeropenem with clavulanate, thiacetazone and clofazimine
reatment  recommendations  for  MDR-TB  include  an
ntensive treatment  phase  of  6—8  months  (4  months
fter culture  conversion)  with  5—6  effective  drugs
hat preferably  include  PZA,  a  FQ  (LFX/GFX/MFX),
n injectable  agent  (KAN/AMI/CAP/VIO),  and  2—3
ther second-line  drugs.  EMB  and  high-dose  INH
ay also  be  included  as  additional  drugs  in  some
ases. The  injectable  agent  may  be  discontinued
fter 8 months;  however,  a  continuation  phase
ith 4 effective  drugs  should  last  for  ≥20  months
18 months  after  culture  conversion)  [16,53]. One
tudy reported  a  shorter  duration  of  treatment
or MDR-TB  patients  who  had  not  been  previously
reated with  second-line  drugs.  Treatment  of  HIV-
eronegative  Bangladeshi  MDR-TB  patients  with  a
-month regimen  containing  PZA,  EMB,  GFX,  and
FZ, as  well  as  a  4-month  intensive  initiation  phase
dditionally  containing  KAN,  PTA,  and  high-dose
NH, cured  ∼90%  of  patients  [54].
Adverse  reactions  occur  frequently  and  pose  a
hallenge  in  MDR-TB  treatment.  A  once-monthly
putum-smear  examination,  culture,  and  DST  pre-
ict response  to  treatment  and  should  be  carried
ut until  sputum  culture-negative  status  has  been
chieved  [16,17,53]. Surgery  could  also  be  consid-
red in  speciﬁc  cases  when  an  insufﬁcient  number
f second-line  drugs  are  available  and  the  patient
as localized  lesions  and  can  tolerate  surgery  [55].
The outcome  of  MDR-TB  treatment  is  highly  vari-
ble  (from  <40%  to  ∼97%)  [16,53,56]. A recent  study
eported  a  pooled  treatment  success  rate  of  75%.
he treatment  success  rate  was  higher  in  patients
ho received  7—8  months  of  initial  intensive-phase
reatment  with  5 drugs  and  a  continuation  phase
ith 4  drugs  (total  treatment  duration  ≥24  months)
i
l
o
i57]. Patients  who  died  during  treatment  were  more
ikely to  be  older,  to  be  HIV-coinfected,  to  have
ore extensive  disease  or  previous  exposure  to  a
igher number  of  anti-TB  drugs,  and/or  to  have
 previous  history  of  treatment  with  second-line
rugs [57].
While  the  principles  of  treatment  are  the  same,
uccessful treatment  of  XDR-TB  is  more  difﬁ-
ult than  that  of  MDR-TB,  even  in  developed
ountries. In  resource-poor  countries,  XDR-TB  is
enerally an  untreatable  disease,  mainly  due  to  the
on-availability  of  drugs  effective  in  killing  semi-
ormant/dormant  bacilli  [18,58]. Thus,  efforts
hould  be  made  to  appropriately  manage  MDR-TB
atients to  avoid  XDR-TB.  The  risk  factors  for  the
evelopment  of  XDR-TB  and  preventive  strategies
nvolved  in  preventing  a patient  with  MDR-TB  from
eveloping  XDR-TB  are  outlined  in  Table  4.  The
ddition  of  PZA,  EMB,  and/or  SM  (if  still  effec-
ive) to  multidrug  regimens  improves  the  prognosis
f XDR-TB  [18,58]. Because  resistance  to  differ-
nt injectables  (KAN/AMI/CAP/VIO)  is  not  complete
nd some  OFX-resistant  strains  remain  susceptible
o MFX  (or  vice  versa),  treatment  of  XDR-TB  should
nclude an  injectable  agent  and  a  FQ  based  on  an
ctual DST  proﬁle  or previous  treatment  history.
dditionally, Group  4  agents  not  used  extensively
n previous  regimens  that  are  more  likely  to  be
ffective,  as  well  as  two  to  several  Group  5  agents,
hould  be  included  [18,58]. Other  experimental
rugs have  also  been  used  occasionally  with  vary-
ng degrees  of  success  [59]. Surgical  resection  may
ower the  bacterial  burden  and  improve  the  clinical
utcome  for  pulmonary  TB  patients  with  local-
zed disease  and  limited  lung  tissue  damage  [55].
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Suspect MDR-TB in:
Patients failing first-line drug treatment/re-treatment/relapse after treatment or
Patients living in close contact with a confirmed case of MDR-TB or
patients in settings  of high prevalence of MDR-TBHIV coinfected
lavage or other Sputum/bronchoalveolar
appropriate sample for extra-pulmonary TB
Smear microscopy 
Positive for acid-fast bacilli
Automated/low-cost 
methods for culture
Positive culture
Identification as M. tuberculosis
Susceptibility testing 
for first-line drugs
Confirmed case of MDR-TB
MTB/RIF or Xpert
Rif. TBINNO-LiPA
Possible case of MDR-TBGenoType
MTBDRplus GenoType
MTBDRplus
Confirmed case of MDR-TB
withtreatmentMDR-TBStart
drugseffectivelikely5-6
Susceptibility testing 
for second-line drugs
GenoType
MTBDRsl
regimentreatmentAdjust
profilesusceptibilitytoaccording
andsmearforpatientofmonitoringRegular
improvementclinicaland/orconversionculture
MTB/RIF or Xpert
Rif. TBINNO-LiPA
Rapid diagnosis Delayed diagnosis
Figure  1  Clinical  approach  to  the  diagnosis  and  management  of  patients  with  suspected  multidrug-resistant  tuber-
culosis.
Table  4  Risk  factors  for  the  development  XDR-TB  and  preventive  strategies  involved  to  prevent  a  patient  with
MDR-TB  to  develop  XDR-TB.
Risk  factors  for  XDR-TB  Preventive  strategies
Insufﬁcient  case  management  Implement  proper  directly  observed  therapy  (DOT)  schedule
Insufﬁcient  case  management  Ensure  sufﬁcient  number  of  likely  effective  drugs  are  used
Previous  treatment  with  second-line  drugs  Avoid  drugs  previously  used  in  treatment  regimens
Easy  availability  of  FQs  and  injectables  for
TB  treatment
Restrict  access  to  FQs  and  injectables  for  TB  treatment
Wider  availability  of  second-line  drugs  Restrict  access  to  second-line  drugs
Non-conversion  or  late  sputum/culture
conversion
Perform  fresh  DST  and  adjust  treatment  regimens
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tiagnosis  and  treatment  of  tuberculosis  
atients  who  fail  to  undergo  sputum  culture  con-
ersion within  6 months  of  starting  treatment  with
everal  anti-TB  drugs  are  more  likely  to  fail  therapy.
rug-resistant TB in children
hildhood  MDR-TB  and  XDR-TB  is  an  emerging  global
pidemic,  but  information  regarding  the  treatment
f pediatric  populations  is  limited.  An  infection
s usually  suspected  if  there  is  known  contact
ith an  adult  source  case  of  MDR-TB/XDR-TB.  Chil-
ren with  TB  often  have  a  negative  culture  due
o a  paucibacillary  load  in  sputum/other  respi-
atory or  gastric  specimens,  making  management
ore difﬁcult  [60]. The  drugs  are  administered  and
etabolized  differently  by  children,  and  adverse
rug  reactions  are  experienced  in  a  different
anner. However,  little  information  on  the  phar-
acokinetic  and  pharmacodynamic  properties  of
econd-line  drugs  in  pediatric  populations  exists
60].  Tuberculous  meningitis  with  MDR-TB  strains
n children  is associated  with  high  mortality  rates.
reatment  of  HIV-coinfected  children  is  even  more
omplex  due  to  additional  problems  of  drug—drug
nteractions with  concomitant  anti-retroviral  ther-
py [61].
rug-resistant TB in HIV-coinfected
atients
IV-coinfection  in  MDR-TB  and  XDR-TB  patients
oses particular  diagnostic  and  therapeutic  chal-
enges,  including  a  paucibacillary  load  in  sputum;
ompliance  with  treatment  regimens  of  ≥10  drugs
or ≥2  years;  poor  drug  absorption  due  to  vomi-
ing and/or  diarrhea;  and  the  emergence  of  drug
esistance,  immune  reconstitution  inﬂammatory
yndrome (worsening  of  clinical  symptoms  and
ppearance  of  new  TB  lesions),  excessive  toxic-
ty, and  additive  adverse  drug  interactions  between
nti-retroviral  agents  and  second-line  anti-TB  drugs
18,61,62].  Rapid  initiation  of  MDR-TB  treatment
ith appropriate  empiric  regimens  at  centers
quipped with  specialized  expertise  to  manage
everal complex  modalities  is  essential  for  achiev-
ng a  good  treatment  outcome.  A  comprehensive
ommunity-based  treatment  and  care  program  that
ncludes a  referral  center  with  TB  expertise  in
esotho,  South  Africa,  recently  reduced  the  rates
f early  mortality  from  MDR-TB  in  HIV-coinfected
ndividuals  from  >70%  to  30%  [63]. However,  the  out-
ome of  XDR-TB  in  HIV-coinfected  patients  remains
ismal, with  mortality  rates  of  ∼80%  within  a few
eeks  of  diagnosis  [18].
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Due  to  an  increasing  prevalence  of  MDR-TB
nd XDR-TB,  there  is  a desperate  need  for  new
ompounds to  treat  drug-resistant  TB  in  better  tol-
rated regimens  of  shorter  duration.  Both  currently
vailable drugs  already  approved  for  human  use  and
ovel drugs  are  being  explored  for  the  treatment  of
DR-TB and  XDR-TB  [64,65].
linical re-evaluation of existing
nti-tubercular drugs
pproximately  20%  of  INH-resistant  M.  tuberculo-
is strains  only  contain  inhA  mutations  and  exhibit
ow-level  resistance  to  INH  and  cross-resistance
o thioamides  [24]. The  currently  recommended
ose can  be  safely  increased  2—3  times,  and
igh-dose INH  therapy  (10—15  mg/kg)  effectively
vercomes low-level  resistance  and  reduces  the
acterial burden  without  an  increased  risk  of  INH-
elated toxicity  [54].  Daily  adult  dosages  of  RIF
600 mg)  can  also  be  safely  increased  to  1200  mg
n most  patients,  which  doubles  its  early  bacteri-
idal activity.  The  efﬁcacy  and  drug  tolerance  of
igh-dose  RIF  are  being  studied  because  it  shows
he potential  to  shorten  the  treatment  duration  of
rug-susceptible  TB  to  4  months  [66].  Additionally,
5—20% of  RIF-resistant  strains  with  speciﬁc  rpoB
utations  remain  susceptible  to  RBU,  making  RBU
 useful  second-line  drug  for  the  treatment  of  these
nfections  [24,29].
Phase  III  trials  are  currently  underway  to  eval-
ate whether  treatment  duration  for  pulmonary
B in  newly  diagnosed  adults  infected  with  drug-
usceptible  strains  can  be  shortened  to  4  months
y the  substitution  of  GFX  for  EMB  or  MFX
or either  EMB  or  INH  (ClinicalTrials.gov,  Trial
dentiﬁers: NCT00216385  and  NCT00864383).  A
ourth-generation  FQ  (DC-159a)  is  4-  to  32-fold
ore potent  than  other  currently  available  FQs
including  MFX)  and  is  also  active  against  some
Q-resistant MDR  M.  tuberculosis  strains  carrying
ommon  gyrA  mutations,  implying  its  utility  for
he treatment  of  some  FQ-resistant  MDR-TB  and
DR-TB strains  [67]. DC-159a  is  also  being  tested
or its  potential  to  shorten  the  duration  of  drug-
usceptible TB  [68].
Phenothiazines  (such  as  thioridazine  or  TDZ)
nterfere with  several  metabolic  pathways  in
. tuberculosis. Phenothiazines  also  inhibit  the
xpression  and  activity  of  efﬂux  pumps  that  con-
ribute to  the  multidrug-resistant  phenotype  of  M.
uberculosis  and  thus  increase  the  efﬁcacy  of less-
ffective  anti-TB  drugs.  Thus,  the  combination  of
DZ with  less  effective  antibiotics  contributes  to
he management  of  MDR-TB  and  XDR-TB  [69].
S.  Ahmad,  E. Mokaddas
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New drugs under clinical evaluation and
preclinical development
Some  anti-TB  drugs  currently  at  various  stages  of
clinical evaluation  or  preclinical  development  are
listed in  Table  5  and  are  described  below.
Bedaquiline  (TMC207),  a  diarylquinoline,  has  a
novel mechanism  of  action  and  potent  activity
against M.  tuberculosis. It  inhibits  the  proton  trans-
fer chain  by  binding  to  subunit  c  (atpE)  of  ATP
synthase. The  killing  of  actively  dividing  bacilli  is
initially slow  and  time-dependent,  while  killing  is
more rapid  and  concentration-dependent  for  non-
replicating  intracellular  bacilli  (persisters).  Thus,
bedaquiline  may  shorten  the  treatment  duration
of drug-susceptible  pulmonary  TB  and  MDR-TB
[65,70].  Bedaquiline  shows  synergistic  activity  with
PZA, and  its  inclusion  in  multidrug  regimens  for
MDR-TB  patients  signiﬁcantly  reduced  the  time  to
culture conversion  and  the  development  of  resis-
tance to  companion  drugs  [71,72]. Bedaquiline  has
completed  phase  II  trials  and  was  recently  granted
conditional approval  by  the  FDA  for  the  treatment
of selected  MDR-TB  patients.  Phase  III  trials  to  eval-
uate its  efﬁcacy  in  sputum  smear-positive  MDR-TB
patients  are  being  planned  (ClinicalTrials.gov;  Trial
Identiﬁer: NCT01600963).
Two potent  derivatives  (PA-824  and
delamanid/OPC-67683)  of  metronidazole  have
been recently  synthesized  and  affect  mycolic  acid
synthesis  in  M.  tuberculosis. Both  drugs  require
nitroreductive activation  and  are  active  (potency
of delamanid  >PA-824)  against  both  drug-sensitive
and MDR  strains  of  M.  tuberculosis.  The  drugs  are
also active  (delamanid  >RIF)  against  anaerobic,
non-replicating,  persistent  bacilli  [73]. Novel
three-drug  combinations  containing  PA-824  have
shown the  potential  to  shorten  treatment  dura-
tion for  both  drug-susceptible  and  drug-resistant
tuberculosis in  mice  and  humans  [72,74].  Phase  II
trials to  assess  the  activity,  safety,  and  tolerability
of PA-824  in  different  regimens  for  the  treatment
of patients  with  drug-susceptible  and  pulmonary
MDR TB  are  currently  underway  (ClinicalTrials.gov;
Trial Identiﬁer:  NCT01498419  and  Trial  Identiﬁer:
NCT01691534).  In  murine  models  of  TB,  a  combi-
nation of  delamanid,  RIF,  and  PZA  rapidly  cleared
bacteria from  lung  tissue,  while  the  addition  of
delamanid  to  drug  regimens  for  pulmonary  MDR-TB
patients  was  associated  with  rapid  sputum-culture
conversion at  2  months  and  a  better  prognosis
after 6 months  of  treatment  [75].  Delamanid  is
in phase  III  trials  for  the  treatment  of  pulmonary
MDR-TB patients  (ClinicalTrials.gov;  Trial  Identiﬁer:
NCT01424670). T
ab
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Riagnosis  and  treatment  of  tuberculosis  
A  new  and  more  potent  ethylenediamine  deriva-
ive (SQ109)  is  active  against  EMB-resistant  M.
uberculosis  strains,  implying  a  different  mecha-
ism of  action.  SQ109  targets  MmpL3,  a  membrane
ransporter involved  in  mycolic  acid  synthesis
nd cell  wall  assembly.  SQ109  is  well  tolerated
nd exhibits  a  synergistic  effect  with  RIF,  INH,
nd the  experimental  drugs  bedaquiline  and  PNU-
00480 [76,77].  SQ109  is  currently  in  phase  II
rials for  safety,  tolerability,  and  pharmacoki-
etic evaluation  in  adults  with  smear-positive
ulmonary  TB  (ClinicalTrials.gov;  Trial  Identiﬁer:
CT01218217).
Two more  potent  oxazolidinone  derivatives
PNU-100480  and  AZD5847)  have  been  synthe-
ized to  overcome  the  toxicity  problems  associated
ith extended  (>28  days)  use  of  LZD  for  the
reatment of  MDR-TB  and  XDR-TB  patients  [78].
NU-100480  did  not  show  cross-resistance  with
ny ﬁrst-line  drug.  It also  improved  the  bacteri-
idal activity  of  existing  ﬁrst-line  drugs  as  well  as
xperimental  drugs,  such  as  bedaquiline  and  SQ109
77,79,80].  PNU-100480  is currently  being  evalu-
ted in  phase  II  studies  (ClinicalTrials.gov;  Trial
dentiﬁer:  NCT01225640).  AZD5847  is  also  active
gainst  M.  tuberculosis  isolates  that  are  resis-
ant to  ﬁrst-line  drugs.  Two  phase  1 studies  to
ssess the  safety,  tolerability,  and  pharmacokine-
ics of  oral  doses  of  AZD5847  have  been  completed
ClinicalTrials.gov;  Trial  Identiﬁers:  NCT01037725
nd NCT01116258).  Phase  II  trials  for  the  treat-
ent of  smear-positive  pulmonary  TB  are  being
arried  out  (ClinicalTrials.gov;  Trial  Identiﬁer:
CT01516203).
Other novel  compounds  have  also  been  devel-
ped and  are  in  various  stages  of  preclinical
evelopment.  A  nitro-benzothiazinone  derivative,
TZ043, shows  potent  (>INH)  bactericidal  activity
gainst drug-susceptible,  MDR,  and  XDR  M.  tuber-
ulosis  strains  [81]. BTZ043  is  a  prodrug  requiring
eductive activation  and  acts  as  a  suicide  inhibitor
f DprE1,  which  is  involved  in  the  synthesis  of  cell
all arabinan,  lipoarabinomannan,  and  arabino-
alactan.  BTZ043  showed  additive  or  synergistic
nteractions with  several  approved  or  experimen-
al anti-TB  drugs  [82]. N-(2-(4-methoxyphenoxy)
thyl)-3,5-dinitrobenzamide  (DNB1),  which  is  struc-
urally related  to  BTZ043,  also  requires  activation
y DprE1  and  blocks  the  synthesis  of  lipoarabino-
annan and  arabinogalactan.  DNB1  exhibits  cross-
esistance  with  BTZ043,  but  it  is  more  potent  than
TZ043 against  drug-susceptible  and  XDR-TB  strains
nd exhibits  lower  toxicity  [83]. A  new  dipiperidine
nalog (SQ609)  inhibited  intracellular  growth  of  M.
uberculosis  inside  macrophages  and  was  effective
n a  murine  model  of  TB  [84]. A  capuramycin
b
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nalog  (SQ641)  targets  phospho-N-acetylmuramyl-
entapeptide translocase  1  (TL1),  an  essential
nzyme involved  in  cell  wall  biosynthesis.  SQ641  is
ore potent  than  the  ﬁrst-line  drugs  INH  and  RIF
gainst  M.  tuberculosis  and  is  also  active  against
DR-TB  strains.  It  shows  synergistic  activity  with
rst-line  drugs  and  SQ109.  Other  water-soluble
nalogs of  SQ641  have  also  been  synthesized  and
mproved  intracellular  killing  of  M.  tuberculo-
is [85]. CPZEN-45,  a  semi-synthetic  analog  of
aprazamycin,  is  active  in  vitro  against  both  repli-
ating and  non-replicating  (dormant)  bacilli  and
hows potent  activity  against  drug-susceptible  and
DR M.  tuberculosis  strains.  CPZEN-45  was  effec-
ive in  a  murine  model  of  TB  during  infection  with
rug-susceptible  and  XDR  M.  tuberculosis  strains
86].
onclusion
he  global  TB  epidemic  mainly  afﬂicts  the  eco-
omically  weaker  sections  of  society,  mostly  in
eveloping  countries.  A  lack  of  resources  for
ational TB  control  programs  in  most  develop-
ng countries  during  the  last  2—3  decades  of  the
0th century  resulted  in  poor  case  detection  due
o insensitive  diagnostic  procedures  and  low  cure
ates resulting  from  an inadequate  supply  of  anti-
B drugs.  Incomplete  or  inappropriate  therapy  due
o the  inability  of  poor  patients  to  pay  for  drugs  for
 long  duration,  the  poor  quality  of  anti-TB  drugs
n some  countries,  and  non-adherence  to  treat-
ent resulted  in  the  evolution  of  drug-resistant  M.
uberculosis  strains.  Inadequate  control  measures
y health  care  providers  and  a  lack  of low-cost  cul-
ure and  drug-susceptibility  testing  procedures  for
ubercle bacilli  ampliﬁed  resistance  levels  further
eading  to  the  emergence  and  spread  of  multidrug-
esistant M.  tuberculosis  strains.  Today,  MDR-TB
as become  prevalent  throughout  the  world,  and
DR-TB strains  are  rapidly  emerging.  Rapid  diag-
osis and  wider  availability  of  second-line  drugs
hrough  national  TB  control  programs  are  vital  for
he successful  management  of  drug-resistant  TB
nd MDR-TB  in  developing  countries.  With  renewed
ommitment  and  concerted  worldwide  efforts,  low-
ost and  relatively  rapid  culture-based  methods
ave been  recently  developed  for  the  diagnosis  and
ST of  M.  tuberculosis  in  resource-poor  settings.
ecent advances  in  understanding  the  molecular
asis of  drug  resistance  in  M.  tuberculosis  have  also
esulted in  the  development  of  rapid  tests  for  the
olecular  diagnosis  of  drug-resistant  TB  and  MDR-
B. Nucleic  acid-based  tests,  including  line  probe
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[88  
assays  and  Xpert  MTB/RIF,  for  the  rapid  diagno-
sis of  TB,  RIF  resistance,  and  MDR  in  pulmonary
specimens are  sufﬁciently  advanced  for  routine
use; however,  they  are  still  too  expensive  for  most
developing countries.  Although  some  of  these  tests
are being  offered  to  developing  countries  at a
reduced  price,  other  low-cost  and  simpler  tests
that use  untreated  sputum,  blood,  or  urine  and
require little  hands-on  time  and  equipment  are
highly desirable.  Rapid  diagnostic  procedures  and
recent guidelines  for  the  aggressive  treatment  of
patients with  several  active  drugs  have  enabled
the proper  management  of  MDR-TB  patients  in
both developed  and  developing  countries.  Success-
ful eradication  of  TB  requires  new  drugs  and  new
drug regimens  of  shorter  duration.  There  has  been
some advancement  in  TB  drug  development  during
the last  few  years,  and  some  new  drugs  are  in  the
late stages  of  clinical  development.  However,  the
number of  these  agents  that  will  actually  reach  the
market as  effective,  affordable,  and  safe  anti-TB
drugs  is unknown.
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